🔗 Share this article

While the US continues making sweeping revisions to its vaccine recommendations, one figure has emerged somewhat surprisingly: Høeg, a US-based physician and public health researcher who rose to prominence by questioning Covid vaccinations throughout the global health crisis and has concentrated on potential fatalities after Covid immunization in her brief time at the FDA.

Planned Shifts to Childhood Vaccine Schedule

Health officials planned to unveil sweeping revisions to the pediatric immunization program in December, aligning the US with the Danish vaccine program, according to reports – a major change that would put the US out of alignment with many the world with no evidence for improved outcomes. This reveal has been delayed until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

Consolidating Power at the Regulatory Body

This interim role may indicate a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a increased emphasis upon dismantling already-approved vaccines at the FDA.

Høeg has often pushed for discontinuing some pediatric shot schedules in the US to become more similar to the Danish model, a country with comprehensive healthcare and a number of inhabitants approximately the population of the state of Wisconsin.

To date public appearances, she has kept her attention on vaccination policy – typically the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has little discernible background in medication creation, regulation or administrative roles, which has been customary for former directors of the biologics center. She has served at the FDA as a top consultant to the agency head and CBER since spring.

“She doesn’t seem to have the necessary background” for leading the CDER, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a large organization. She has no expertise in industry regulation.”

Former directors of the center would “grasp legal statutes and the science of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she lacks the type of experience that prior appointees who ran the center have had.”

This division has an vast portfolio at the FDA, the former commissioner pointed out.

“The public just pays attention on the novel medication approvals, but the generic drug division authorizes thousands of generic drugs. There is also a biosimilars program, over-the-counter program and more, and all of those need to be looked after,” Dr. Woodcock said. “The thing you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a significant administrative aspect to the job, which manages over 5,000 personnel. “It’s a massive administrative position, if you execute it properly,” she concluded.

Agency Reaction and Contentious Policies

When asked about inquiries about Dr. Høeg's qualifications and whether this assignment represents increased cooperation among FDA leaders on immunizations, a representative said that the “concerns are based on flawed presumptions”.

“Her resume aligns with the responsibilities of her position,” the spokesperson stated, noting the period Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s controversial expedited review system, a disputed one-day drug-approval program that reportedly troubled her predecessors. “By what process are these therapies being chosen for this voucher program? Who takes the calls?” Dr. Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards laxer rules of pharmaceuticals, except for immunizations.”

Documented History on Immunizations

Concerning immunizations, Høeg has a clearer, if problematic, track record, critics said. She published a analysis using non-validated crowd-sourced reports to estimate the frequency of myocarditis following COVID-19 vaccination. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccinations are more dangerous than they are.

Among her “policy goals” for the incoming government featured revising guidelines for recently developed shots and discontinuing “non-essential” immunizations, she remarked post-election on a audio program. At the FDA, Høeg has allegedly suggested excluding teenage boys from obtaining COVID-19 vaccines.

“She is an all-around dogmatist who commences with her conclusions and reverse-engineers to fit the evidence in a very misleading, untruthful manner,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg aligned with other contrarians, {like|